News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Curis, Inc. (CRIS) Presents Data on PI3K and HDAC Inhibitor CUDC-907 at the 2011 American Association for Cancer Research-National Cancer Institute-European Organization for Research and Treatment of Cancer Symposium



11/16/2011 6:45:27 AM

LEXINGTON, Mass.--(BUSINESS WIRE)--Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced the presentation of data in a poster presentation at the 2011 AACR-EORTC-NCI International Conference on Molecular Targets and Cancer Therapeutics in San Francisco, California. The poster presentation was titled “Anti-tumor activity of CUDC-907, a single small molecule inhibitor that targets both PI3K and HDAC, in hematologic cancer models” and was presented by Rudi Bao, M.D., Ph.D., Curis’ Senior Director of Oncology.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES